Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an update on the ongoing IKEMA study (NCT03275285), a Phase III trial investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) versus carfilzomib and dexamethasone (Kd) for patients with relapsed/refractory (R/R) multiple myeloma. Isatuximab is a monoclonal antibody therapy targeting CD38. A very good partial response or better was achieved in 72.6% of patients receiving Isa-Kd treatment versus 56.1% receiving Kd treatment alone. Progression-free survival (PFS) was not reached at a median follow-up of 20.7 months for patients treated with Isa-Kd versus PFS at 19.15 months for patients treated with Kd. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.